非侵襲糖尿病治療市場レポート：2030年までの動向、予測、競合分析

非侵襲糖尿病治療の動向と予測

世界の非侵襲糖尿病治療市場は、2024年から2030年にかけてCAGR 5.6％で成長すると予測されます。この市場の主な促進要因は、糖尿病有病率の上昇と糖尿病患者の自己治療志向の高まりです。世界の非侵襲糖尿病治療市場は、病院、在宅医療、診療所市場に機会があり、将来性が期待されます。

セグメント別非侵襲糖尿病治療

この調査には、世界の非侵襲糖尿病治療のタイプ別、用途別、地域別の予測が含まれています。

非侵襲糖尿病治療市場の洞察

Lucintelの予測では、吸入インスリンが予測期間中に最も高い成長を遂げる見込みです。

同市場では、在宅医療が予測期間中に最も高い成長を遂げると予測されています。

北米は、人口の糖尿病有病率が高く、同地域に主要企業が存在することから、予測期間中に最も高い成長が見込まれます。

よくある質問

Q1.市場の成長予測は：

A1.世界の非侵襲糖尿病治療市場は、2024年から2030年にかけてCAGR 5.6％で成長すると予測されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、糖尿病有病率の上昇と糖尿病患者の自己治療志向の高まりです。

Q3.市場の主要セグメントは：

A3.非侵襲糖尿病治療市場の将来性は、病院、在宅医療、診療所市場での機会により有望視されています。

Q4.市場の主要企業は：

A4.非侵襲糖尿病治療の主要企業は以下の通りです：

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、吸入インスリンが予測期間中に最も高い成長を遂げると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.北米は糖尿病人口が多く、主要企業が存在するため、予測期間中に最も高い成長が見込まれます。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の非侵襲糖尿病治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の非侵襲糖尿病治療市場の動向（2018～2023年）と予測（2024～2030年）
• 世界の非侵襲糖尿病治療市場（タイプ別）
  • 経口インスリン
  • 経頬インスリン
  • 点眼インスリン
  • 吸入インスリン
  • 経鼻インスリン
  • 経皮
  • その他
• 世界の非侵襲糖尿病治療市場（用途別）
  • 病院
  • 在宅医療
  • 診療所
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別世界の非侵襲糖尿病治療市場
• 北米の非侵襲糖尿病治療市場
• 欧州の非侵襲糖尿病治療市場
• アジア太平洋地域の非侵襲糖尿病治療市場
• その他地域非侵襲糖尿病治療市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の非侵襲糖尿病治療市場におけるタイプ別の成長機会
  • 世界の非侵襲糖尿病治療市場における用途別の成長機会
  • 地域別の世界の非侵襲糖尿病治療市場の成長機会
• 世界の非侵襲糖尿病治療市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の非侵襲糖尿病治療市場の能力拡大
  • 世界の非侵襲糖尿病治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Non-Invasive Diabetes Therapy Trends and Forecast

The future of the global non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets. The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Non-Invasive Diabetes Therapy by Segment

The study includes a forecast for the global non-invasive diabetes therapy by type, application, and region.

Non-Invasive Diabetes Therapy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Oral Insulin
• Buccal Insulin
• Ocular Insulin
• Inhaled Insulin
• Nasal Insulin
• Transdermal
• Others

Non-Invasive Diabetes Therapy Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Home Care Settings
• Clinics
• Others

Non-Invasive Diabetes Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Non-Invasive Diabetes Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive diabetes therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive diabetes therapy companies profiled in this report include-

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Non-Invasive Diabetes Therapy Market Insights

Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Within this market, home care setting is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Features of the Global Non-Invasive Diabetes Therapy Market

Market Size Estimates: Non-invasive diabetes therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Non-invasive diabetes therapy market size by type, application, and region in terms of value ($B).

Regional Analysis: Non-invasive diabetes therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the non-invasive diabetes therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive diabetes therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for non-invasive diabetes therapy market?

Answer: The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the non-invasive diabetes therapy market?

Answer: The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

Q3. What are the major segments for non-invasive diabetes therapy market?

Answer: The future of the non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets.

Q4. Who are the key non-invasive diabetes therapy market companies?

Answer: Some of the key non-invasive diabetes therapy companies are as follows:

• Bio Tex
• Calisto Medical
• Dexcom
• Bayer
• ACON Laboratories

Q5. Which non-invasive diabetes therapy market segment will be the largest in future?

Answer: Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Q6. In non-invasive diabetes therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the non-invasive diabetes therapy market by type (oral insulin, buccal insulin, ocular insulin, inhaled insulin, nasal insulin, transdermal, and others), application (hospitals, home care settings, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Non-Invasive Diabetes Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Non-Invasive Diabetes Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Non-Invasive Diabetes Therapy Market by Type
  • 3.3.1: Oral Insulin
  • 3.3.2: Buccal Insulin
  • 3.3.3: Ocular Insulin
  • 3.3.4: Inhaled Insulin
  • 3.3.5: Nasal Insulin
  • 3.3.6: Transdermal
  • 3.3.7: Others
• 3.4: Global Non-Invasive Diabetes Therapy Market by Application
  • 3.4.1: Hospitals
  • 3.4.2: Home Care Settings
  • 3.4.3: Clinics
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Non-Invasive Diabetes Therapy Market by Region
• 4.2: North American Non-Invasive Diabetes Therapy Market
  • 4.2.1: North American Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.2.2: North American Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
• 4.3: European Non-Invasive Diabetes Therapy Market
  • 4.3.1: European Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.3.2: European Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
• 4.4: APAC Non-Invasive Diabetes Therapy Market
  • 4.4.1: APAC Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.4.2: APAC Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
• 4.5: ROW Non-Invasive Diabetes Therapy Market
  • 4.5.1: ROW Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
  • 4.5.2: ROW Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Type
  • 6.1.2: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Application
  • 6.1.3: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Region
• 6.2: Emerging Trends in the Global Non-Invasive Diabetes Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Non-Invasive Diabetes Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Diabetes Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bio Tex
• 7.2: Calisto Medical
• 7.3: Dexcom
• 7.4: Bayer
• 7.5: ACON Laboratories